For most CML patients, the introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) has changed this fatal disease into a manageable chronic condition [1, 2]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.